театр оперы и балета имени мусы джалиля казань афиша
Главное меню:
Интересное
театр оперы и балета имени мусы джалиля казань афиша, US8697359B1 - CRISPR-Cas systems and methods for altering expression of , (12) United States Patent (10) Patent No.: US 8,697,359 B1 Zhang (45 , Broad Institute awarded first patent for engineered CRISPR-Cas9 system, PTAB Decides CRISPR Interference -- No interference-in-fact, Revolutionizing genome editing with CRISPR/Cas9: patent battles and , Analytics for US Patent No. 8697359, CRISPR-Cas systems and methods for , CRISPR-Cas systems and methods for altering - Justia Patents Search.
CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats) have recently been harnessed as genome editing tools in a wide range of species. The engineered CRISPR-Cas9 system allows researchers to mutate or change the expression of genes in living cells, including those of humans. The family of Cas9 nucleases (also known as Cas5, Csn1, or Csx12) recognizes DNA targets in complex with RNA guides. Researchers can now harness the engineered system to home in on specific nucleic acid sequences and cut the DNA at those precise targets. The cuts modify the activity of the targeted genes, allowing researchers to study the genes' function., The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors., Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may significantly simplify the method ology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases..
U.S. Patent No. 8,697,359 is assigned to the Broad Institute and the Massachusetts Institute of Technology and includes claims to the engineered CRISPR-Cas9 system and methods of using the system., US Patent No. 8,697,359 (Broad) 1. A method of altering expression of at least one gene product comprising: introducing into a eukaryotic cell containing and expressing a DNA molecule having a target sequence and encoding the gene product an engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)--CRISPR associated (Cas) (CRISPR-Cas) system , While Doudna’s and Charpentier’s groups may have published first and have received a number of awards for their work in this field, it is Zhang who has been awarded the first patent on the basic CRISPR technology – US Patent No. 8,697,359, ‘CRISPR-Cas systems and methods for altering expression of gene products’ (the “Zhang patent , The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors., The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors., Just a few months later, in December 2012, the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University filed their first CRISPR-related patent application under fast-track review process. Broad Institute further filed 11 more applications. The United States Patent and Trademark Office (USPTO) granted a patent (US Patent No. 8,697,359) to Broad Researchers on .